Correlation between Psoriasis Area Severity Index and Dermatology Life Quality Index in psoriasis
Keywords:
Psoriasis, PASI Score, DLQIAbstract
Introduction Several validated dermatology-specific measurement tools are used globally to quantify the extent to which a skin disorder affects an individual’s quality of life. Methods A cross-sectional study was performed enrolling 60 patients of psoriasis. Patients were evaluated for psoriasis severity using the Psoriasis Area and Severity Index (PASI) and its correlation with Dermatology Life Quality Index (DLQI) was assessed. Results PASI and DLQI were found to have significant correlation (r= 0.266; p=0.044) but the degree of correlation was much lower than that found in European studies. However, analysis done after data stratification did not show a significant relationship between the two scores except in males (r=0.415; p=0.006) and in patients with disease duration between 1-6 years (r=0.579; p=0.002). Conclusion The correlation we found between PASI and DLQI was weaker than that reported previously in other populations. Further validation of culturally relevant and disease specific quality of life measuring instruments is needed to capture the true impact of skin diseases on patients’ lives. Currently, DLQI fails to encompass some clinically important endpoints and may not be much relevant for routine clinical practice in our society.References
Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, Guo C, Dellavalle R, Grada A, Wong P, La Vecchia C. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;16(8):743180.
Ograczyk A, Miniszewska J, Kępska A, Zalewska-Janowska A. Itch, disease coping strategies and quality of life in psoriasis patients. Postepy Dermatol Alergol. 2014;31(5):299.
Al-Mutairi N, Eassa BE, Nair V. Measurement of vitamin D and cathelicidin (LL-37) levels in patients of psoriasis with co-morbidities. Indian J Dermatol Venereol Leprol. 2013;79(4):492.
Schons KRR, Beber AAC, Beck MdO, Monticielo OA. Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features. An Bras Dermatol. 2015;90(3):314-9.
Hawro T, Zalewska A, Hawro M, Kaszuba A, Królikowska M, Maurer M. Impact of psoriasis severity on family income and quality of life. J Eur Acad Dermatol Venereol. 2015;29(3):438-43.
Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Sump Proc. 2004;9(2):169-180.
Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333-7.
Nayak PB, Girisha BS, Noronha TM. Correlation between disease severity, family income, and quality of life in psoriasis: A study from South India. Indian Dermatol Online J. 2018;9(3):165.
Soltandehghan K, Najafi-Ghezeljeh T. Relationship Between Quality of Life and Disease Severity in Patients with Psoriasis. NPT. 2017;4(3):143-53.
Khawaja, A.R., Bokhari, S.M.A., Rasheed, T., Shahzad, A., Hanif, M., Qadeer, F. and Jafferany, M. Disease severity, quality of life, and psychiatric morbidity in patients with psoriasis with reference to sociodemographic, lifestyle, and clinical variables: a prospective, cross-sectional study from Lahore, Pakistan. Prim Care Companion CNS Disord. 2015;17(3):26260.
Finlay AY, Khan G. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6.
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997-103.
